Further, oligonucleotide‐based therapies for specific ALS subgroups have entered clinical trials14 that is, tofersen (BIIB067), an antisense drug targeting SOD1 (NCT02623699)15 and BIIB078 to be used in C9ORF72‐ALS patients (NCT03626012). This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.